ixazomib

Known as: {(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic Acid 
An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma… (More)
  • table 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2016
Review
2016
Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in… (More)
  • figure 1
Is this relevant?
2016
2016
 
Is this relevant?
2016
2016
Proteasome inhibitors have become an integral part of myeloma therapy. Considerable efforts have gone into optimizing this… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2015
2015
This phase 2 trial was designed to evaluate ixazomib, an orally bioavailable proteasome inhibitor, in patients with myeloma who… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
2015
2015
Purpose Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple… (More)
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Ixazomib is the first investigational oral proteasome inhibitor to be studied clinically. In this phase 1 trial, 60 patients with… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving survival, attention is increasingly… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed… (More)
Is this relevant?